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Available online 22 October 2015Asia, which comprises over 4 billion people, makes up approx-
imately 60 percent of the world's population. Its population is
currently seen to be rising faster than Europe's or America's. Asia's
population is also ageing and experiencing longer life expectancy,
with a signiﬁcant projected increase in proportion of people over
65 years of age, in the next few decades.
Prostate cancer is the 3rd most common cancer amongst men
worldwide, and incidence rates are highest in western countries
and lowest in Asian countries. Recent data from Asia have shown
steady increase in prostate cancer incidence in the past few de-
cades, with some countries such as Korea, experiencing a rapid rise.
The average mortality rate of prostate cancer in Asian countries is
3.8 per 100,000, but current data shows a rising trend in a number
of countries.1,2 Although prostate cancer incidence is lower in Asia
compared to western countries, the mortality-to-incidence rate
ratio is generally higher in Asian countries (up to 0.63), compared
to that of Caucasian population in the USA (up to 0.17).3 These
numbers differ across Asia, with Japan, Korea, and Singapore having
lower mortality-to-incidence rate ratios than Vietnam, Malaysia,
Philippines, and China. As for China, there is also a huge variability
between Shanghai and other provinces.* Corresponding author: Edmund Chiong (edmund_chiong@nuhs.edu.sg).
http://dx.doi.org/10.1016/j.prnil.2015.10.011
p2287-8882 e2287-903XMultiple factors including increasing age, genetic differences
(including differences in prevalence of TMPRSS2-ERG fusion, PTEN
inactivation and polymorphisms), environmental factors, changing
dietary habits, increased obesity and increasing adoption of pros-
tate cancer screening have been proposed to be responsible for the
differences and rise in incidence rates, in Asia.2 Ethnic difference,
relatively lower intensity of screening, late detection of cancers in
advanced or metastatic stages, and variations in resource for access
to therapy, are thought to contribute to the higher mortality rate in
Asian countries.
There is a need for better understanding of the variations in
biology, more data on the epidemiological trends, and collection of
quality data on management and outcomes, for prostate cancer in
Asia. Individualised screening and treatment strategies for each
country, depending on epidemiological characteristics and
resource availability, needs to be developed.Conﬂict of interest
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